Figure S1 from Proteogenomic approaches for the identification of NF1/neurofibromin-depleted estrogen receptor positive breast cancers for targeted treatment
Beom-Jun Kim(Baylor College of Medicine), Eric C. Chang(Baylor College of Medicine), Dan Ye(Southwestern Medical Center), Purba Singh(Baylor College of Medicine), Matthew V. Holt(Baylor College of Medicine), Ariella B. Hanker(Southwestern Medical Center), Meenakshi Anurag(Baylor College of Medicine), Arun Sreekumar(University of Michigan–Ann Arbor), Hilda Kennedy(Baylor College of Medicine), George Miles(Baylor College of Medicine), Nada Mohamed(Baylor Scott & White Health), Diana Fandino(Baylor College of Medicine), Bora Lim(Baylor College of Medicine), Jonathan T. Lei(Baylor College of Medicine), Matthew J. Ellis(Guardant (United States)), Jaya Ruth Asirvatham(Baylor Scott & White Medical Center - Temple), Yongchao Dou(Baylor College of Medicine), Emmanuel Bikorimana(Southwestern Medical Center), Susan G. Hilsenbeck(Baylor College of Medicine), Yunguan Wang(Cincinnati Children's Hospital Medical Center), María del Rosario Chica-Parrado(Southwestern Medical Center), Anran Chen(Baylor College of Medicine), Bing Zhang(Baylor Genetics), Jianheng Peng(Baylor College of Medicine)
Cited by 0
Related Papers
The molecular portraits of breast tumors are conserved across microarray platforms
|BMC Genomics|2006|1.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k